Juan Gómez Rivas: Recent advances in managing BCR after local treatment for prostate cancer

Juan Gómez Rivas, Urologist, shared an article on X:

“Recent advances in managing biochemical recurrence (BCR) after local treatment for prostate cancer (PCa).

We analyzed 19 studies (9117 patients) to compare different salvage therapies post-radical prostatectomy (RP) or radiation therapy (RT). Results show that combining RT with hormone therapy offers significant improvements in metastatic-free survival (MFS).

Key findings:

• RT + hormone therapy = MFS
•  Best RT-based strategy: Prostate bed RT + elective nodal RT + ADT
• Top hormone-based strategy: Enzalutamide + ADT for MFS and OS.

For high-risk BCR or post-RT recurrence, consider adding ARSI (androgen receptor signaling inhibitors) to ADT.

These combinations represent the next step in PCa care, ensuring better outcomes for patients.

Tittle: Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis

Authors: Akihiro Matsukawa , Takafumi Yanagisawa , Tamas Fazekas , Marcin Miszczyk , Ichiro Tsuboi , Mehdi Kardoust Parizi,Ekaterina Laukhtina , Jakob Klemm , Stefano Mancon , Keiichiro Mori , Shoji Kimura , Jun Miki , Juan Gomez Rivas , Timo F W Soeterik , Thomas Zilli , Derya Tilki , Steven Joniau , Takahiro Kimura , Shahrokh F Shariat and Pawel Rajwa. 

Source: Juan Gómez Rivas/X